Skip to main content
PMC home page
SpringerPlus logoLink to SpringerPlus
. 2016 Jul 19;5(1):1108. doi: 10.1186/s40064-016-2801-5

Worldwide research productivity on tramadol: a bibliometric analysis

Waleed M Sweileh 1,✉, Naser Y Shraim 2, Sa’ed H Zyoud 3, Samah W Al-Jabi 3
PMCID: PMC4949195  PMID: 27478725

Abstract

Background

Pain management and safe use of analgesics is an important medical issue. Tramadol is an old analgesic with controversial properties. Evaluation of worldwide scientific output on tramadol has not been explored. Therefore, the main objective of this study was to give a bibliometric overview of global research productivity on tramadol.

Methods

SciVerse Scopus was used to retrieve and quantitatively and qualitatively analyze worldwide publications on tramadol.

Results

A total of 2059 original and review research articles on tramadol were retrieved from Scopus. Forty-six documents (2.23 %) were published in Anesthesia and Analgesia Journal whereas 30 (1.46 %) were published in Arzneimittel Forschung Drug Research Journal. Retrieved tramadol documents were published from 71 countries and appeared in 160 peer reviewed journals. Although the United States of America (259; 12.86 %) had the largest contribution to tramadol publications; the contribution by other countries like Turkey (232; 11.27) India (189; 8.09 %) and Germany (176; 8.56 % was not far away from that of USA. The most productive institution was Grunenthal, Germany (47; 2.28 %) followed by Tehran University of Medical Sciences, Iran (29; 1.41 %), and, Ortho-McNeil Pharmaceutical Incorporated, USA (25; 1.21 %). Of the 2059 documents, there were 370 documents about dependence. The leading institution in documents pertaining to tramadol dependence was Grunenthal GmbH (18; 4.86 %) followed by Ortho-McNeil Pharmaceutical Incorporated (17; 4.59 %).

Conclusions

The current study showed that there is an obvious interest in tramadol research. More efforts are needed to clarify the abuse potential and safety profile of tramadol to help in determining the legal status of tramadol. Collaboration among pharmaceutical industry, clinical researchers and academic institutions can improve research quantity and quality on tramadol.

Keywords: Bibliometric, Tramadol, Scopus, Pain management

Background

Search for best methods of pain management is as old as mankind (Gildenberg 1997; Greenblatt et al. 1997). However, only in the past several decades did research about pain management showed great momentum and became a cornerstone in the medical field. The initiation of several international peer reviewed journals specialized in the field of pain/anesthesia has contributed to this positive momentum in pain research. Furthermore, the discovery and development of potent and unique analgesics have also increased attention to pain research. No doubt that the increase in prevalence of chronic pain has also stimulated many pharmaceutical companies to search for new analgesic medications those bear ideal characteristics. Despite the ongoing research and development in the field of pain, no ideal analgesic drug has been found yet. A study that discussed the characteristics of more than 50 analgesics introduced in the past 50 years concluded that despite intense research efforts, there is no real novel analgesic drug discovery and an ideal analgesic is not yet available (Kissin 2010). In 1977, tramadol, a new and atypical opioid analgesic medication, was introduced and marketed by the German pharmaceutical company, Grünenthal GmbH. Since that time, many articles have been published about tramadol and its unique pharmacology and toxicology. Tramadol is unique in that it affects serotonin and norepinephrine systems in addition to its weak μ-opioid receptor agonist activity (Dayer et al. 1994, 1997; Grond and Sablotzki 2004; Epstein et al. 2006; Raffa 2008; Reeves and Burke 2008). Therefore, tramadol has dual mechanism of action; µ opioid agonist and a serotonin/norepinephrine reuptake inhibitor (Raffa 2013; Vazzana et al. 2015). That is why tramadol causes adverse effects pertaining to elevated brain serotonin levels (serotonin syndrome) especially when co-administered with selective serotonin reuptake inhibitors (SSRI) drug class (Nelson and Philbrick 2012; Beakley et al. 2015). Another important pharmacological aspect of tramadol is its metabolism by CYP2D6 which exhibits wide polymorphism leading to variation in toxic and therapeutic effects of tramadol (Lassen et al. 2015; Ibrahim et al. 2016).

The abuse potential of tramadol is still an ongoing controversy (Friderichs et al. 1978; Murano et al. 1978; Richter et al. 1985; Ehrenreich and Poser 1993; Liu et al. 1999; Aknine et al. 2000; Yates et al. 2001; Brinker et al. 2002; Ripamonti et al. 2004; Naslund and Dahlqvist 2003; Woody et al. 2003; Skipper et al. 2004; Soyka et al. 2004). Understanding progress made in pain management research in general and about tramadol in particular requires periodic assessment of how scientific research in this topic is advancing. Bibliometric analysis, a statistical method for literature evaluation, is commonly used for assessment of research activity in any particular filed (Wallin 2005). Several bibliometric studies on pain related topics have been recently published (Robert et al. 2008a, b; Dubner 2009; Mogil et al. 2009; Onyeka and Chukwuneke 2014). However, based on author’s best knowledge, no bibliometric analysis has been published about analgesic drugs, particularly about a controversial medication like tramadol. In this study we planned to give a bibliometric overview of tramadol publications through analysis of temporal research productivity and analysis of highly cited articles in tramadol field. This study is important for those in the field of clinical pharmacology and medicine since it will give them a comprehensive look on current research trends on tramadol and future status of pain management in general and role of tramadol in pain management guidelines.

Methods

In this study, traditional bibliometric indicators were applied and presented. Such indicators have been explained in previous studies by the same authors. Standard competition ranking (SCR) was used to rank productive journals, countries, authors and institutions. The h-index (Hirsch 2005) was used to assess quantity and quality of research productivity by authors, countries and institutions. The journal impact factor (IF) obtained from the Journal Citation Report (JCR; Web of Knowledge) 2014 science edition by Thomson Reuters and the SCImago Journal Rank (SJR) indicator (available at: http://www.scimagojr.com/SCImagoJournalRank.pdf) were used as a quality indicator for journal strength and reputation. The adjustment index (AI) was used to stratify productivity with income and population size and was obtained using the following equation: “AI = [total number of publications for the country/gross domestic product (GDP) per capita of the country] × 1000, where the GDP per capita = GDP/population of the country” (Sweileh et al. 2013; Zyoud et al. 2014e, 2015a). In this study, the keyword entered into Scopus search engine was “tramadol” in the “Article Title”. All subject areas were selected and the time interval of the analysis was set up to December 31st, 2013. Analysis was restricted to original and review articles. Citation analysis was completed within 1 day on July 29th, 2015 to avoid bias due to daily in database update. The extracted data were tabulated and analyzed according to the indicators found in previous bibliometric studies (Sweileh et al. 2014; Zyoud et al. 2014b, c, e, f, 2015a, d).

Results

A total of 2429 research articles on tramadol were retrieved. Of the 2429 articles, there were 1958 (80.61 %) original journal articles, 101 (4.16 %) review articles, 146 (6.01 %) letters, 67 (2.76 %) conference papers, and 157 (6.47 %) other types of publications such as editorial, notes, book chapters, erratum and undefined. Analysis in this manuscript was based on 2059 documents that were original research articles and reviews. The 2059 articles were written in 23 different languages. The main language encountered was English (n = 1687; 80.68 %) followed distantly by Turkish (n = 87; 4.16 %), Chinese (n = 72; 3.44 %), German (n = 62; 2.97 %), Spanish (n = 56; 2.68 %), French (n = 24; 1.15 %), Italian (n = 21; 1.00 %), and 16 other languages (82; 3.92 %). The number of published documents about tramadol in the past 5 years (2008–2013) has increased by approximately 15-folds compared with the time interval from 1978 to 1988 (Table 1). The first article on tramadol was published in 1978. Retrieved tramadol articles were published from 71 countries and appeared in 160 peer reviewed journals. Top ten productive countries on tramadol research are shown in Table 2. Tramadol research and publications were produced by countries from different world regions and even from countries outside Europe and North America. Although the largest number of articles about tramadol was produced by the USA (259; 12.58 %); the contribution by other countries like Turkey (232; 11.27 %), India (189; 8.09 %) and Germany (176; 8.56 %) was not far away from that of the USA (Table 2). It is noteworthy that Turkey surpassed Germany and other European countries in tramadol research.

Table 1.

Worldwide growth of tramadol research activity

Time interval Number of published documents
N = 2059		 %
2009–2013 778 37.79
2004–2008 586 28.46
2003–1999 383 18.6
1994–1998 198 9.62
1989–1993 63 3.06
<1989 51 2.48
Open in a new tab

Table 2.

Top 10 countries in tramadol research

SCRa Country Articles (%) Total citation H-index Average citation Median (Q1–Q3) of citation Collaborations with foreign countries Number (%)a of documents with international authors Adjustment index
1st United States 259 (12.58) 9273 53 19 (9–46) 38.44 26 61 (23.55) 4.74
2nd Turkey 232 (11.27) 2067 24 3 (1–13) 8.91 4 8 (3.45) 22.00
3rd India 189 (8.09) 1019 16 2 (0–6) 5.39 5 8 (4.23) 115.85
4th Germany 176 (8.56) 5533 40 17 (6–37) 31.44 17 36 (20.45) 3.69
5th China 134 (6.51) 835 16 2 (0–7.25) 6.23 4 10 (7.64) 17.64
6th Iran 101 (4.90) 1094 18 5 (2–11.5) 10.83 4 8 (7.92) 19.08
7th Italy 99 (4.81) 1609 22 6 (1–11) 7.01 15 24 (24.24) 2.83
8th Spain 80 (3.89) 1112 22 8.5 (1–24) 13.90 14 29 (36.25) 2.64
9th United Kingdom 64 (3.11) 2238 26 19.5 (6.25–41.5) 34.97 15 24 (37.50) 1.40
10th France 50 (2.43) 952 16 9 (2–20.25) 19.04 13 20 (40.00) 1.17
Open in a new tab

aPercentage of documents with international authors from the total number of documents for each country

SCR standard competition ranking, Q1–Q3 lower quartile–upper quartile

The total citations of retrieved articles was 36,275, with an average of 17.62 citations per article as recorded in Scopus on July 29th, 2015. The h-index of tramadol publications was 74. List of most commonly cited articles on tramadol is shown in Table 3 (Raffa et al. 1992, 1993; Vickers et al. 1992; Lee et al. 1993; Poulsen et al. 1996; Harati et al. 1998; Sindrup et al. 1999; Scott and Perry 2000; Xia et al. 2000; Grond and Sablotzki 2004). Those about the potential mechanism of action and potential role of tramadol in treatment of neuropathic pain were most commonly cited. Two of the top 10 cited articles were published from the same research group, the Raffa et al., group present in the USA. Table 4 shows top 10 productive journals involved in tramadol research. Forty-six articles (2.24 %) were published in Anesthesia and Analgesia whereas 30 (1.46 %) were published in Arzneimittel Forschung: Drug Research. Of the top 10 journals, six were in the field of anesthesia and pain, three in the field of pharmacology, therapeutics and drug research and one in the field of clinical pharmacology and anesthesia. Of the top 10 journals, two were Turkish journals while the others were based either in USA or Europe. When the journals were screened for IF, three journals of the top productive ones were not listed in ISI JCR and the remaining were listed and had an IF <5.

Table 3.

Top 10 cited articles in tramadol-related research

SCRa Authors Journal Cited by
1st Raffa et al. (1992) Journal of Pharmacology and Experimental Therapeutics 802
2nd Harati et al. (1998) Neurology 416
3rd Grond and Sablotzki (2004) Clinical Pharmacokinetics 402
4th Lee et al. (1993) Drugs 375
5th Xia et al. (2000) Bulletin of Hunan Medical University 360
6th Scott and Perry (2000) Drugs 331
7th Raffa et al. (1993) Journal of Pharmacology and Experimental Therapeutics 325
8th Vickers et al. (1992) Anaesthesia 292
9th Poulsen et al. (1996) Clinical Pharmacology and Therapeutics 290
10th Sindrup et al. (1999) Pain 273
Open in a new tab

SCR standard competition ranking

aEqual articles have the same ranking number and then a gap is left in the ranking numbers

Table 4.

Top 10 journals in which tramadol-related documents were published

SCRa Journal N (%)
N = 2059		 IF SJR
1st Anesthesia and Analgesia 46 (2.23) 3.472 1.50
2nd Arzneimittel Forschung: Drug Research 30 (1.46) 0.701 0.25
2nd Agri: The Journal of The Turkish Society of Algology 30 (1.46) N/A 0.21
4th British Journal of Anaesthesia 28 (1.36) 4.853 1.84
4th European Journal of Pharmacology 28 (1.36) 2.532 0.87
6th European Journal of Anaesthesiology 27 (1.31) 2.942 0.96
7th Paediatric Anaesthesia 19 (0.92) 1.850 0.84
7th Journal of Anaesthesiology Clinical Pharmacology 19 (0.92) N/A 0.30
9th Clinical Therapeutics 18 (0.87) 2.731 0.80
9th European Journal of Clinical Pharmacology 18 (0.87) 2.966 1.03
9th Egyptian Journal of Anaesthesia 18 (0.87) N/A 0.15
Open in a new tab

SCR standard competition ranking, IF impact factor, SJR standard journal ranking, N/A not available

aEqual journals have the same ranking number and then a gap is left in the ranking numbers

Table 5 presents scientific subjects of the 2059 articles. As expected, the majority were in the field of medicine (1303; 63.38 %) followed by pharmacology/toxicology/pharmaceutics (721; 35.07 %) and chemistry (189; 9.19 %). Of the 2059 documents, there were 370 documents about dependence. The leading institution in documents pertaining to tramadol dependence was Grunenthal GmbH (18; 4.86 %) followed by Ortho-McNeil Pharmaceutical Incorporated (17; 4.59 %). Table 6 shows top 10 highly productive institutions which published most about tramadol. The most productive institution was Grunenthal, Germany (47; 2.44 %) followed by Tehran University of Medical Sciences, Iran (25; 1.30 %), and, Ortho-McNeil Pharmaceutical Incorporated, USA (25; 1.3 %). Table 7 presents the top 10 productive authors on about tramadol, along with their affiliations. Half of the top prolific authors were from USA and seven were affiliated with academic institutions.

Table 5.

Top 10 subject fields in tramadol-related documents

SCRa Subject area N (%)b
N = 2059
1st Medicine 1303 (63.38)
2nd Pharmacology, toxicology and pharmaceutics 721 (35.02)
2nd Chemistry 189 (9.18)
4th Biochemistry, genetics and molecular biology 177 (8.60)
5th Neuroscience 132 (6.41)
6th Veterinary 119 (5.78)
7th Environmental science 46 (2.23)
8th Psychology 42 (2.04)
9th Agricultural and biological sciences 30 (1.46)
9th Dentistry 30 (1.46)
9th Nursing 30 (1.46)
Open in a new tab

SCR standard competition ranking, USA United States of America

aEqual research areas have the same ranking number and then a gap is left in the ranking numbers

bThe total % exceeds 100 % because of overlap among subjects

Table 6.

Top 10 productive institution in tramadol-related research

SCRa Institute N (%)
N = 2059 (100 %)		 Affiliation of the institute
1st Grunenthal GmbH 47 (2.28) Germany
2nd Tehran University of Medical Sciences 29 (1.41) Iran
3rd Ortho-McNeil Pharmaceutical Incorporated 25 (1.21) USA
4th Çukurova Üniversitesi 24 (1.17) Turkey
5th R. W. Johnson Pharmaceutical Research Institute 17 (0.83) USA
6th Universidade de Sao Paulo 16 (0.78) Brazil
7th University of Tennessee, Knoxville 13 (0.63) USA
8th Universität Bonn 12 (0.58) Germany
8th Università degli Studi di Roma La Sapienza 12 (0.58) Italy
8th Poznan University of Medical Sciences 12 (0.58) Poland
8th Bethune International Peace Hospital of the PLA 12 (0.58) China
Open in a new tab

SCR standard competition ranking, USA United States of America

aEqual institutions have the same ranking number and then a gap is left in the ranking numbers

Table 7.

Top 10 authors in tramadol research

SCRa Author name Total number of articles Affiliation Country
1st R. B. Raffa 18 Temple University, School of Pharmacy, Philadelphia USA
2nd M. Giorgi 16 University of Pisa, Department of Veterinary Clinical Sciences, Pisa Italy
3rd M. Kamin 15 Ortho Biotech Products, L.P., Bridgewater USA
3rd N. R. Rosenthal 15 Ortho-McNeil Pharmaceutical Incorporated, Raritan USA
5th S. K. Cox 14 University of Tennessee, Knoxville, Department of Biomedical and Diagnostic Sciences, Knoxville USA
6th Y. Gunes 13 Cukurova University, Department of Anesthesiology, Adana Turkey
6th D. Jordan 13 Ortho-McNeil Pharmaceutical Incorporated, Raritan USA
6th D. Ozcengiz 13 Cukurova University, Department of Anesthesiology, Adana Turkey
9th G. Saccomanni 12 Universita di Pisa, Dipartimento di Farmacia, Pisa Italy
9th K. Minami 12 Emergency Life-Saving Technique Academy of Tokyo, Hachioji Japan
9th G. Isik 12 Çukurova University, Faculty of Medicine, Department of Anesthesiology, Adana Turkey
Open in a new tab

SCR standard competition ranking, USA United States of America

aEqual authors have the same ranking number and then a gap is left in the ranking numbers

Discussion

Evidence-based pain management requires exploration of efficacy and safety of various analgesics as presented in literature. Our study analyzed 2059 research articles retrieved from Scopus, a large databases equipped with search options that facilitate citation and comparative analysis (de Granda-Orive et al. 2011). Scopus covers higher number of journals in different subject areas and allows citation analysis which made it very suitable for bibliometric analysis compared to other databases (Tadmouri and Bissar-Tadmouri 2004; Falagas et al. 2008; Kulkarni et al. 2009; de Granda-Orive et al. 2011).

Tramadol was developed in early 1960s by Grunenthal, a German pharmaceutical company. Tramadol entered the West German market in late 1970s with the trade name Tramal®. Approximately 20 years later, tramadol was introduced to the US market. Currently, tramadol is available in 100 countries under different trade names. Although tramadol is unique in having dual mechanism of action, its introduction to the worldwide market was slow and cautious. A possible reason for this slow introduction was the uncertainty regarding safety and abuse potential. However, reports and clinical trials have shown that tramadol has lesser toxic profile and better tolerability than oral traditional nonsteroidal anti-inflammatory drugs (NSAIDs) or commonly used opioids (Preston et al. 1991; Adams et al. 2006; Epstein et al. 2006). A study carried out to compare the abuse potential among NSAIDs, codeine, placebo and tramadol has found that abuse potential for tramadol is significantly lower than that of codeine (Adams et al. 2006). On the other hand, reports about other serious side effects like seizure have been reported (Tobias 1997; Raffa and Stone 2008; Sen et al. 2009; Singh et al. 2009; Talaie et al. 2009; Taghaddosinejad et al. 2011; Yarkan Uysal et al. 2011; Boostani and Derakhshan 2012; Mehrpour 2013).

In our study, bibliometric techniques were applied to give an overview on worldwide published research on tramadol. The first publication about tramadol appeared in 1978 followed by rapid increase, particularly after 1995 which coincide with the year of introduction in the US market. The first article about tramadol as analgesic was published by Rost, A., Schenck, E.G. in Arzneimittel-Forschung/Drug Research in 1978 as a comparative clinical study (Rost and Schenck 1978). The discovery and identification of tramadol and its unique mechanism of action lead to the development of a newer tramadol-like agent named tapentadol which is currently available in the market and promoted to have better safety profile than tramadol (Giorgi et al. 2012; Mercadante et al. 2012, 2013; Cepeda et al. 2013; Gohler et al. 2013; Lee et al. 2013; Schwittay et al. 2013; Singh et al. 2013; Fejos et al. 2014).

An average of 17.62 (median = 6) citations per article was obtained in this study. This finding means that tramadol is an interesting topic for scientific research community. Furthermore, the fact that the top 10 productive countries and top 10 productive institutions in tramadol research included countries and institutes outside the Americas and Europe suggest that tramadol research is of interest to many nations. It was obvious that non-academic institutions, particularly pharmaceutical companies, were involved heavily in tramadol research for human or veterinary use (Wu et al. 2001; Teppema et al. 2003; Giorgi et al. 2009a, b). In addition, research about tramadol and its potential use in premature ejaculation gave further momentum to tramadol research (Safarinejad and Hosseini 2006; Salem et al. 2008; Bar-Or et al. 2012). At the official level, research interest in tramadol was motivated by the debate about the legal status and whether to schedule or un-schedule tramadol. In Sweden and in several states in the USA, including New York, Arkansas, Illinois, Kentucky, Mississippi, North Dakota, Oklahoma, Tennessee, Wyoming, and West Virginia have categorized tramadol as a schedule IV controlled substance. In most countries of the world, the legal status of tramadol is currently under re-evaluation.

Finally, the authors believe that this study, like all other bibliometric studies, has few limitations that have been explained in previous bibliometric studies (Li et al. 2011; Sweileh et al. 2013; Zyoud et al. 2014a, d, 2015b, c; Zyoud 2015). Such limitations include the use of Scopus database; the use of “tramadol” word as a title keyword in the search engine; and the restriction of analysis to original articles and article reviews. However, despite all this, the current study will be of great value for people in pain management policy and those involved in research pertaining to analgesia.

Conclusions

Tramadol is an analgesic with controversial properties which made it an appealing topic for researchers from different scientific disciplines. Research output about tramadol was not confined to particular country. More research efforts are needed to shed light on the abuse potential and the non-analgesic therapeutic benefits of tramadol. Research activity about tramadol needs to be directed toward minimizing its side effects. Such research activity can be achieved through collaboration among people in pharmaceutical industry, clinical practice and academic institutions.

Authors’ contributions

All authors were involved in drafting the article, and all authors approved the final version to be submitted for publication. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank An-Najah National University for giving the opportunities to access most recent information sources such as Scopus database.

Competing interests

The authors declare that they have no competing interests.

Contributor Information

Waleed M. Sweileh, Email: waleedsweileh@yahoo.com, Email: waleedsweileh@najah.edu

Naser Y. Shraim, Email: shraim.n@gmail.com

Sa’ed H. Zyoud, Email: saedzyoud@yahoo.com

Samah W. Al-Jabi, Email: samahjabi@yahoo.com

References

  1. Adams EH, Breiner S, Cicero TJ, Geller A, Inciardi JA, Schnoll SH, Senay EC, Woody GE. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31(5):465–476. doi: 10.1016/j.jpainsymman.2005.10.006. [DOI] [PubMed] [Google Scholar]
  2. Aknine X, Varescon-Pousson I, Boissonnas A. Tramadol dependence in a previous heroin addict. Ann Med Interne. 2000;151(Suppl. B):B34–B35. [PubMed] [Google Scholar]
  3. Bar-Or D, Salottolo KM, Orlando A, Winkler JV. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol. 2012;61(4):736–743. doi: 10.1016/j.eururo.2011.08.039. [DOI] [PubMed] [Google Scholar]
  4. Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18(4):395–400. [PubMed] [Google Scholar]
  5. Boostani R, Derakhshan S. Tramadol induced seizure: a 3-year study. Casp J Intern Med. 2012;3(3):484–487. [PMC free article] [PubMed] [Google Scholar]
  6. Brinker A, Bonnel RA, Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry. 2002;159(5):881. doi: 10.1176/appi.ajp.159.5.881. [DOI] [PubMed] [Google Scholar]
  7. Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013;14(10):1227–1241. doi: 10.1016/j.jpain.2013.05.010. [DOI] [PubMed] [Google Scholar]
  8. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs. 1994;47(Suppl. 1):3–7. doi: 10.2165/00003495-199400471-00003. [DOI] [PubMed] [Google Scholar]
  9. Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs. 1997;53(Suppl. 2):18–24. doi: 10.2165/00003495-199700532-00006. [DOI] [PubMed] [Google Scholar]
  10. de Granda-Orive JI, Alonso-Arroyo A, Roig-Vazquez F. Which data base should we use for our literature analysis? Web of Science versus SCOPUS. Arch Bronconeumol. 2011;47(4):213. doi: 10.1016/j.arbres.2010.10.007. [DOI] [PubMed] [Google Scholar]
  11. Dubner R. A bibliometric analysis of the pain journal as a representation of progress and trends in the field. Pain. 2009;142(1–2):9–10. doi: 10.1016/j.pain.2009.01.003. [DOI] [PubMed] [Google Scholar]
  12. Ehrenreich H, Poser W. Dependence on tramadol. Clin Investig. 1993;72(1):76. doi: 10.1007/BF00231123. [DOI] [PubMed] [Google Scholar]
  13. Epstein DH, Preston KL, Jasinski DR. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol. 2006;73(1):90–99. doi: 10.1016/j.biopsycho.2006.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, scopus, web of science, and google scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–342. doi: 10.1096/fj.07-9492LSF. [DOI] [PubMed] [Google Scholar]
  15. Fejos I, He Y, Volgyi G, Kazsoki A, Sun J, Chen W, Sohajda T, Szente L, Jiang X, Beni S. Tapentadol enantiomers: synthesis, physico-chemical characterization and cyclodextrin interactions. J Pharm Biomed Anal. 2014;88:594–601. doi: 10.1016/j.jpba.2013.10.005. [DOI] [PubMed] [Google Scholar]
  16. Friderichs E, Felgenhauer F, Jongschaap P, Osterloh G. Pharmacological studies on analgesia, dependence on and tolerance of tramadol, a potent analgetic drug (author’s transl) Arzneimittelforschung. 1978;28(1a):122–134. [PubMed] [Google Scholar]
  17. Gildenberg PL. History of pain management. In: Greenblatt SH, Dagi TF, Epstein MH, editors. A history of neurosurgery. Park Ridge: American Association of Neurological Surgeons; 1997. pp. 439–464. [Google Scholar]
  18. Giorgi M, Del Carlo S, Saccomanni G, Lebkowska-Wieruszewska B, Turini V, Kowalski C. Biopharmaceutical profile of tramadol in the dog. Vet Res Commun. 2009;33(Suppl. 1):189–192. doi: 10.1007/s11259-009-9278-4. [DOI] [PubMed] [Google Scholar]
  19. Giorgi M, Saccomanni G, Lebkowska-Wieruszewska B, Kowalski C. Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. Vet J. 2009;180(2):253–255. doi: 10.1016/j.tvjl.2007.12.011. [DOI] [PubMed] [Google Scholar]
  20. Giorgi M, Meizler A, Mills PC. Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. Vet J. 2012;194(3):309–313. doi: 10.1016/j.tvjl.2012.05.019. [DOI] [PubMed] [Google Scholar]
  21. Gohler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013;51(4):338–348. doi: 10.5414/CP201722. [DOI] [PubMed] [Google Scholar]
  22. Greenblatt SH, Dagi TF, Epstein MH. A history of neurosurgery: in its scientific and professional contexts. Park Ridge: The American Association of Neurological Surgeons; 1997. [Google Scholar]
  23. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923. doi: 10.2165/00003088-200443130-00004. [DOI] [PubMed] [Google Scholar]
  24. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842–1846. doi: 10.1212/WNL.50.6.1842. [DOI] [PubMed] [Google Scholar]
  25. Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci USA. 2005;102(46):16569–16572. doi: 10.1073/pnas.0507655102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ibrahim SF, Ali MM, Gouda AS, Rashed LA. Association between the severity of tramadol toxicity and some CYP2D6 allelic variants in Egyptian tramadol intoxicated patients. Emerg Med. 2016;6:303. doi: 10.4172/2165-7548.1000303. [DOI] [Google Scholar]
  27. Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg. 2010;110(3):780–789. doi: 10.1213/ANE.0b013e3181cde882. [DOI] [PubMed] [Google Scholar]
  28. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of science, scopus, and google scholar for articles published in general medical journals. JAMA. 2009;302(10):1092–1096. doi: 10.1001/jama.2009.1307. [DOI] [PubMed] [Google Scholar]
  29. Lassen D, Damkier P, Brosen K. The pharmacogenetics of tramadol. Clin Pharmacokinet. 2015;54(8):825–836. doi: 10.1007/s40262-015-0268-0. [DOI] [PubMed] [Google Scholar]
  30. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46(2):313–340. doi: 10.2165/00003495-199346020-00008. [DOI] [PubMed] [Google Scholar]
  31. Lee HK, Lebkowska-Wieruszewska B, Kim TW, Kowaski CJ, Giorgi M. Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. Vet J. 2013;198(3):620–624. doi: 10.1016/j.tvjl.2013.09.011. [DOI] [PubMed] [Google Scholar]
  32. Li XQ, Tao KM, Zhou QH, Ling CQ. Scientific publications from mainland China, Taiwan, and Hong Kong in integrative and complementary medicine journals: a ten-year literature survey. Am J Chin Med. 2011;39(4):639–649. doi: 10.1142/S0192415X11009081. [DOI] [PubMed] [Google Scholar]
  33. Liu ZM, Zhou WH, Lian Z, Mu Y, Ren ZH, Cao JQ, Cai ZJ. Drug dependence and abuse potential of tramadol. Zhongguo Yao Li Xue Bao. 1999;20(1):52–54. [PubMed] [Google Scholar]
  34. Mehrpour O. Addiction and seizure ability of tramadol in high-risk patients. Indian J Anaesth. 2013;57(1):86–87. doi: 10.4103/0019-5049.108584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C, Giarratano A, Casuccio A. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28(11):1775–1779. doi: 10.1185/03007995.2012.739151. [DOI] [PubMed] [Google Scholar]
  36. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, Giarratano A, Casuccio A. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29(6):661–666. doi: 10.1185/03007995.2013.791617. [DOI] [PubMed] [Google Scholar]
  37. Mogil JS, Simmonds K, Simmonds MJ. Pain research from 1975 to 2007: a categorical and bibliometric meta-trend analysis of every research paper published in the journal, Pain. Pain. 2009;142(1–2):48–58. doi: 10.1016/j.pain.2008.11.012. [DOI] [PubMed] [Google Scholar]
  38. Murano T, Yamamoto H, Endo N, Kudo Y, Okada N, Masuda Y, Yano I. Studies on dependence on tramadol in rats. Arzneimittelforschung. 1978;28(1a):152–158. [PubMed] [Google Scholar]
  39. Naslund S, Dahlqvist R. Treatment with tramadol can give rise to dependence and abuse. Lakartidningen. 2003;100(9):712–714. [PubMed] [Google Scholar]
  40. Nelson EM, Philbrick AM. Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. Ann Pharmacother. 2012;46(12):1712–1716. doi: 10.1345/aph.1Q748. [DOI] [PubMed] [Google Scholar]
  41. Onyeka TC, Chukwuneke FN. Pain research in Africa: a ten-year bibliometric survey. J Anesth. 2014;28(4):511–516. doi: 10.1007/s00540-013-1767-5. [DOI] [PubMed] [Google Scholar]
  42. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996;60(6):636–644. doi: 10.1016/S0009-9236(96)90211-8. [DOI] [PubMed] [Google Scholar]
  43. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. 1991;27(1):7–17. doi: 10.1016/0376-8716(91)90081-9. [DOI] [PubMed] [Google Scholar]
  44. Raffa RB. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther. 2008;33(2):101–108. doi: 10.1111/j.1365-2710.2008.00897.x. [DOI] [PubMed] [Google Scholar]
  45. Raffa RB. Drugs with mixed action and combinations: emphasis on tramadol. In: Gebhart GF, Schmidt RF, editors. Encyclopaedia of pain. Berlin, Heidelberg: Springer; 2013. pp. 1071–1075. [Google Scholar]
  46. Raffa RB, Stone DJ., Jr Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther. 2008;325(2):500–506. doi: 10.1124/jpet.108.137273. [DOI] [PubMed] [Google Scholar]
  47. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–285. [PubMed] [Google Scholar]
  48. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993;267(1):331–340. [PubMed] [Google Scholar]
  49. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today. 2008;44(11):827–836. doi: 10.1358/dot.2008.44.11.1308916. [DOI] [PubMed] [Google Scholar]
  50. Richter W, Barth H, Flohe L, Giertz H. Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung. 1985;35(11):1742–1744. [PubMed] [Google Scholar]
  51. Ripamonti C, Fagnoni E, De Conno F. Withdrawal syndrome after delayed tramadol intake. Am J Psychiatry. 2004;161(12):2326–2327. doi: 10.1176/appi.ajp.161.12.2326. [DOI] [PubMed] [Google Scholar]
  52. Robert C, Caillieux N, Wilson CS, Gaudy JF, Arreto CD. World orofacial pain research production: a bibliometric study (2004–2005) J Orofac Pain. 2008;22(3):181–189. [PubMed] [Google Scholar]
  53. Robert C, Wilson CS, Donnadieu S, Gaudy JF, Arreto CD. Bibliometric analysis of the scientific literature on pain research: a 2006 study. Pain. 2008;138(2):250–254. doi: 10.1016/j.pain.2008.05.016. [DOI] [PubMed] [Google Scholar]
  54. Rost A, Schenck EG. The effect of tramadol and other analgesics on the pain threshold in human dental pulp (author’s transl) Arzneimittelforschung. 1978;28(1a):181–183. [PubMed] [Google Scholar]
  55. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006;26(1):27–31. doi: 10.1097/01.jcp.0000195110.79027.3f. [DOI] [PubMed] [Google Scholar]
  56. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008;5(1):188–193. doi: 10.1111/j.1743-6109.2006.00424.x. [DOI] [PubMed] [Google Scholar]
  57. Schwittay A, Schumann C, Litzenburger BC, Schwenke K. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists. J Pain Palliat Care Pharmacother. 2013;27(3):225–234. doi: 10.3109/15360288.2013.816406. [DOI] [PubMed] [Google Scholar]
  58. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs. 2000;60(1):139–176. doi: 10.2165/00003495-200060010-00008. [DOI] [PubMed] [Google Scholar]
  59. Sen H, Ozkan S, Dagli G. Epileptic seizure during patient-controlled analgesia with tramadol. Eur J Anaesthesiol. 2009;26(5):447. doi: 10.1097/EJA.0b013e32831de521. [DOI] [PubMed] [Google Scholar]
  60. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83(1):85–90. doi: 10.1016/S0304-3959(99)00079-2. [DOI] [PubMed] [Google Scholar]
  61. Singh NK, Haleem S, Gupta V, Ansari MM, Khan AQ, Moh DM. Tramadol induced seizure. Is isoniazid the culprit? Neurosciences. 2009;14(3):294–295. [PubMed] [Google Scholar]
  62. Singh DR, Nag K, Shetti AN, Krishnaveni N. Tapentadol hydrochloride: a novel analgesic. Saudi J Anaesth. 2013;7(3):322–326. doi: 10.4103/1658-354X.115319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Skipper GE, Fletcher C, Rocha-Judd R, Brase D. Tramadol abuse and dependence among physicians. JAMA. 2004;292(15):1818–1819. doi: 10.1001/jama.292.15.1818-b. [DOI] [PubMed] [Google Scholar]
  64. Soyka M, Backmund M, Hasemann S. Tramadol use and dependence in chronic noncancer pain patients. Pharmacopsychiatry. 2004;37(4):191–192. doi: 10.1055/s-2004-827177. [DOI] [PubMed] [Google Scholar]
  65. Sweileh WM, Zyoud SH, Sawalha AF, Abu-Taha A, Hussein A, Al-Jabi SW. Medical and biomedical research productivity from Palestine, 2002–2011. BMC Res Notes. 2013;6:41. doi: 10.1186/1756-0500-6-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sweileh WM, Zyoud SH, Al-Jabi SW, Sawalha AF. Substance use disorders in Arab countries: research activity and bibliometric analysis. Subst Abuse Treat Prev Policy. 2014;9:33. doi: 10.1186/1747-597X-9-33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Tadmouri GO, Bissar-Tadmouri N. A major pitfall in the search strategy on PubMed. Saudi Med J. 2004;25(1):7–10. [PubMed] [Google Scholar]
  68. Taghaddosinejad F, Mehrpour O, Afshari R, Seghatoleslami A, Abdollahi M, Dart RC. Factors related to seizure in tramadol poisoning and its blood concentration. J Med Toxicol. 2011;7(3):183–188. doi: 10.1007/s13181-011-0168-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Talaie H, Panahandeh R, Fayaznouri M, Asadi Z, Abdollahi M. Dose-independent occurrence of seizure with tramadol. J Med Toxicol. 2009;5(2):63–67. doi: 10.1007/BF03161089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Teppema LJ, Nieuwenhuijs D, Olievier CN, Dahan A. Respiratory depression by tramadol in the cat: involvement of opioid receptors. Anesthesiology. 2003;98(2):420–427. doi: 10.1097/00000542-200302000-00023. [DOI] [PubMed] [Google Scholar]
  71. Tobias JD. Seizure after overdose of tramadol. South Med J. 1997;90(8):826–827. doi: 10.1097/00007611-199708000-00010. [DOI] [PubMed] [Google Scholar]
  72. Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, Garcia ML, Silva AM, Souto EB. Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015;70:234–238. doi: 10.1016/j.biopha.2015.01.022. [DOI] [PubMed] [Google Scholar]
  73. Vickers M, O’flaherty D, Szekely S, Read M, Yoshizumi J. Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia. 1992;47(4):291–296. doi: 10.1111/j.1365-2044.1992.tb02166.x. [DOI] [PubMed] [Google Scholar]
  74. Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005;97(5):261–275. doi: 10.1111/j.1742-7843.2005.pto_139.x. [DOI] [PubMed] [Google Scholar]
  75. Woody GE, Senay EC, Geller A, Adams EH, Inciardi JA, Schnoll S, Munoz A, Cicero TJ. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride) Drug Alcohol Depend. 2003;72(2):163–168. doi: 10.1016/S0376-8716(03)00198-4. [DOI] [PubMed] [Google Scholar]
  76. Wu WN, McKown LA, Gauthier AD, Jones WJ, Raffa RB. Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica. 2001;31(7):423–441. doi: 10.1080/00498250110057378. [DOI] [PubMed] [Google Scholar]
  77. Xia SL, Luo JG, Tan HY. Analgesic effect of tramadol in the treatment of pulpitis. Hunan Yi Ke Da Xue Xue Bao. 2000;25(4):350–360. [PubMed] [Google Scholar]
  78. Yarkan Uysal H, Bilimgut B, Dikmen B, Inan N, Ulger G, Eruyar S. Epileptic seizure following IV tramadol in a patient with mental retardation and cerebellar ataxia. Pain Med. 2011;12(5):833–836. doi: 10.1111/j.1526-4637.2011.01079.x. [DOI] [PubMed] [Google Scholar]
  79. Yates WR, Nguyen MH, Warnock JK. Tramadol dependence with no history of substance abuse. Am J Psychiatry. 2001;158(6):964. doi: 10.1176/appi.ajp.158.6.964. [DOI] [PubMed] [Google Scholar]
  80. Zyoud SH. Bibliometric analysis on global Catha edulis (khat) research production during the period of 1952–2014. Glob Health. 2015;11:39. doi: 10.1186/s12992-015-0124-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Zyoud SH, Al-Jabi S, Sweileh W, Awang R. A bibliometric analysis of research productivity of Malaysian publications in leading toxicology journals during a 10-year period (2003–2012) Hum Exp Toxicol. 2014;33(12):1284–1293. doi: 10.1177/0960327113514101. [DOI] [PubMed] [Google Scholar]
  82. Zyoud SH, Al-Jabi SW, Sweileh WM. Bibliometric analysis of scientific publications on waterpipe (narghile, shisha, hookah) tobacco smoking during the period 2003–2012. Tob Induc Dis. 2014;12(1):7. doi: 10.1186/1617-9625-12-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Zyoud SH, Al-Jabi SW, Sweileh WM. Worldwide research productivity in the field of electronic cigarette: a bibliometric analysis. BMC Public Health. 2014;14(1):667. doi: 10.1186/1471-2458-14-667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Zyoud SH, Al-Jabi SW, Sweileh WM, Awang R. Assessing the scientific research productivity of a leading toxicology journal: a case study of human & experimental toxicology from 2003 to 2012. SAGE Open Med. 2014;2:2050312114523424. doi: 10.1177/2050312114523424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Zyoud SH, Al-Jabi SW, Sweileh WM, Awang R. A bibliometric analysis of toxicology research productivity in Middle Eastern Arab countries during a 10-year period (2003–2012) Health Res Policy Syst. 2014;12(1):4. doi: 10.1186/1478-4505-12-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Zyoud SH, Al-Jabi SW, Sweileh WM, Awang R. A scopus-based examination of tobacco use publications in Middle Eastern Arab countries during the period 2003–2012. Harm Reduct J. 2014;11(1):14. doi: 10.1186/1477-7517-11-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Zyoud SH, Al-Jabi SW, Sweileh WM. Worldwide research productivity of paracetamol (acetaminophen) poisoning: a bibliometric analysis (2003–2012) Hum Exp Toxicol. 2015;34(1):12–23. doi: 10.1177/0960327114531993. [DOI] [PubMed] [Google Scholar]
  88. Zyoud SH, Al-Jabi SW, Sweileh WM, Al-Khalil S, Alqub M, Awang R. Global methaemoglobinaemia research output (1940–2013): a bibliometric analysis. Springerplus. 2015;4:626. doi: 10.1186/s40064-015-1431-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Zyoud SH, Al-Jabi SW, Sweileh WM, Al-Khalil S, Sawalha AF, Awang R. The Arab world’s contribution to solid waste literature: a bibliometric analysis. J Occup Med Toxicol. 2015;10:35. doi: 10.1186/s12995-015-0078-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Zyoud SH, Al-Jabi SW, Sweileh WM, Waring WS. Scientific research related to calcium channel blockers poisoning: bibliometric analysis in Scopus, 1968–2012. Hum Exp Toxicol. 2015;34(11):1162–1170. doi: 10.1177/0960327115571768. [DOI] [PubMed] [Google Scholar]

Articles from SpringerPlus are provided here courtesy of Springer-Verlag

RESOURCES